丙戊酸钠缓释剂辅助治疗兴奋躁动的精神分裂症及分裂情感障碍的研究  

Clinical evaluation of sodium valproate xr (Depakine) in adjunctive therapy for patients with excitomania associated with schizophrenia and schizoaffective disorder

作　　者：卢伟明[1] 金卫东[1] 沈莹[1] 马永春[1] 童振华[1] 

机构地区：[1]浙江省立同德医院 浙江省精神卫生研究院,杭州310012

出　　处：《中国新药杂志》2006年第15期1291-1293,共3页Chinese Journal of New Drugs

摘　　要：目的:评价丙戊酸钠缓释剂(德巴金)辅助治疗兴奋躁动的精神分裂症以及分裂情感障碍的疗效。方法:对符合CCMD-3精神分裂症、分裂情感障碍诊断标准,且以兴奋躁动为主要表现的患者随机分为试验组43例和对照组47例。试验组应用抗精神病药物(氯氮平、奥氮平、利培酮或奎硫平其中之一)联合德巴金(0．5～1．5 g·d-1),对照组单一使用抗精神病药物,观察6周。结果:两组的症状学变化在治疗前后都具有显著性,但是试验组改善比对照组显著(P<0．05～0．01),不良反应组间比较无统计学差异(P>0．05)。结论:德巴金可协助治疗精神分裂症以及分裂情感障碍的兴奋状态。Objective： To assess the efficacy of sodium valproate XR （Depakine） in adjunctive therapy for patients with excitomania associated with schizophrenia and schizoaffective disorder. Methods： 90 patients with excitomania who were diagnosed by CCMD-3 criteria of schizophrenia and schizoaffective disorder were randomized to receive a combination of conventional antipsychotic and Depakine （0. 5 - 1.5 g·d^-1 , n = 43 ） or conventional antipsychotic alone for 6 weeks. Results： The Depakineadded patients experienced the symptom improvements more significantly than patients receiving conventional therapy alone （P 〈 0.05）. No significant difference in the incidence of adverse events was found between two treatment groups. Conclusion： Depakine can be used in adjunctive therapy for excitomania associated with schizophrenia and schizoaffective disorder.

关 键 词：丙戊酸钠缓释剂 精神分裂症 分裂情感障碍 兴奋状态 

分 类 号：R971.4[医药卫生—药品] R969.4[医药卫生—药学]